A Q&A With Aji Bio-Pharma: Plasmid Manufacturing For Gene Therapies

iStock-1293772874-lab-plasmid-gene therapy-DNA

An increased demand for plasmids for targeted gene therapeutic delivery has made partnering with a CDMO equipped with the capacity, expertise, and equipment for plasmid DNA production critical to a stable therapeutic supply. Ajinomoto Bio-Pharma Services, an industry leader in microbial fermentation, recently hosted a webinar, Plasmid Manufacturing for Gene Therapies: An Outsourcing Partnership, which outlined both the company’s capabilities in the space and some best practices for vetting CDMOs.

As part of the webinar, Dr. Katya McLane, director of process science, and Ron Chantung, director of drug substance for Ajinomoto Bio-Pharma Services, discussed why optimizing, scaling-up, and manufacturing plasmids is necessary for clinical and commercial program success. The pair also highlighted how Aji Bio-Pharma’s proven expertise and capabilities in cGMP production of biotherapeutics enable a strong, client-focused partnership that guarantees market success.

access the Q&A!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma

Ajinomoto Bio-Pharma Services